Research sponsors implement at least one substantial global amendment for nearly 60% of all clinical trial protocols, substantially reducing the number of actual patients screened and enrolled, but leading to significantly longer clinical trial durations and higher costs, a newly completed analysis by the Tufts Center for the Study of Drug Development (CSDD) concludes.
The total median direct cost to implement a substantial amendment for phase II and phase III protocols is $141,000 and $535,000, respectively, according to the Tufts CSDD analysis, which defined a substantial amendment as any change to a protocol on a global level requiring internal approval, followed by approval from the institutional or ethical review board or regulatory authority.
In addition, nearly half of all substantial amendments—most often undertaken to modify study volunteer demographics, eligibility criteria and safety assessment activity—are deemed avoidable by sponsor organizations, Tufts CSDD said.
“The positive news is that unplanned delays, disruptions and costs associated with protocol amendments have spurred the research-based biopharmaceutical industry to identify new approaches to simplify protocol design and reduce the frequency of amendments,” said Ken Getz, associate professor and director of sponsored research at Tufts CSDD. “Our new analysis provides more detailed insight into the impact of amendments and how to anticipate and manage them.”
Among actions drug sponsors are taking to reduce protocol amendments, are piloted and broad use of feasibility review committees, common protocol templates and investigative site and patient feedback panels, Getz said.
Other findings from the analysis, reported in the January/February Tufts CSDD Impact Report, released today, include the following: